Disc Medicine Inc
IRON60.790USD
-1.840-2.94%
收盘 09/19, 16:00（美东）报价延迟15分钟
2.11B总市值
亏损市盈率 TTM
关于 Disc Medicine Inc 公司
Disc Medicine, Inc. 是一家临床阶段生物制药公司，专注于发现、开发和商业化针对患有严重血液病患者的新型治疗方法。该公司的产品线包括用于治疗红细胞生成性卟啉症 (Eps)（包括红细胞生成性原卟啉症 (EPP) 和 X 连锁原卟啉症 (XLP)）和 Diamond-Blackfan 贫血症 (DBA) 的 bitopertin；用于治疗骨髓纤维化贫血 (MF) 和慢性肾病贫血 (CKD) 的 DISC-0974，以及用于治疗真性红细胞增多症 (PV) 和其他血液病的 DISC-3405（以前称为 MWTX-003）。此外，其临床前项目还包括用于治疗与炎症性疾病相关的贫血的 DISC-0998。Bitopertin 是该公司血红素生物合成调节产品组合中的领先候选产品。该公司正在开发 DISC-3405，一种针对跨膜丝氨酸蛋白酶 6 的单克隆抗体，该抗体由 Mabwell Therapeutics, Inc. 授权。
公司简介
公司代码IRON
公司名称Disc Medicine Inc
上市日期Aug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
员工数量84
证券类型Ordinary Share
年结日Aug 12
公司地址321 Arsenal Street, Suite 101
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02472
电话16176749274
网址https://www.discmedicine.com/
公司代码IRON
上市日期Aug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月3日 周三
更新时间: 9月3日 周三
持股股东
股东类型
持股股东
持股股东
占比
Access Industries, Inc.
10.24%
Fidelity Management & Research Company LLC
8.87%
Atlas Venture
6.18%
BlackRock Institutional Trust Company, N.A.
4.93%
Frazier Life Sciences Management, L.P.
4.76%
其他
65.03%
持股股东
持股股东
占比
Access Industries, Inc.
10.24%
Fidelity Management & Research Company LLC
8.87%
Atlas Venture
6.18%
BlackRock Institutional Trust Company, N.A.
4.93%
Frazier Life Sciences Management, L.P.
4.76%
其他
65.03%
股东类型
持股股东
占比
Investment Advisor
37.71%
Investment Advisor/Hedge Fund
18.24%
Hedge Fund
17.94%
Venture Capital
12.84%
Corporation
10.24%
Private Equity
9.90%
Research Firm
1.45%
Sovereign Wealth Fund
0.83%
Individual Investor
0.47%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
2023Q2
190
22.86M
100.53%
+3.93M
2023Q1
169
18.38M
96.84%
-1.35M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Access Industries, Inc.
3.56M
10.27%
--
--
Feb 27, 2025
Fidelity Management & Research Company LLC
3.05M
8.81%
+1.32M
+76.31%
Mar 31, 2025
Atlas Venture
2.38M
6.88%
-125.00K
-4.98%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.75M
5.06%
+219.74K
+14.35%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.75M
5.07%
--
--
Mar 31, 2025
RA Capital Management, LP
1.58M
4.55%
+1.58M
--
Mar 31, 2025
Janus Henderson Investors
1.42M
4.11%
+205.44K
+16.87%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.34M
3.87%
-36.42K
-2.65%
Mar 31, 2025
Wellington Management Company, LLP
2.34M
6.77%
+948.09K
+67.94%
Mar 31, 2025
OrbiMed Advisors, LLC
1.42M
4.09%
-370.55K
-20.75%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
Proshares Ultra Russell 2000
0.06%
Global X Russell 2000 ETF
0.06%
ProShares UltraPro Russell2000
0.06%
First Trust US Equity Opportunities ETF
0.06%
iShares Morningstar Small-Cap Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
Fidelity MSCI Health Care Index ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.93%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.09%
Proshares Ultra Russell 2000
占比0.06%
Global X Russell 2000 ETF
占比0.06%
ProShares UltraPro Russell2000
占比0.06%
First Trust US Equity Opportunities ETF
占比0.06%
iShares Morningstar Small-Cap Value ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.02%
Fidelity MSCI Health Care Index ETF
占比0.02%
Fidelity Nasdaq Composite Index ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
公告日期
类型
比率
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
